Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Date:6/12/2008

inancial resources will allow us to continue to execute on our strategy to acquire rights to patented, development stage drug candidates, advance the candidates through proof-of-principle clinical trials and generate value through partnering or our own commercial efforts."

Total revenue for the fourth quarter of fiscal year 2008 was $3,301,000 compared to $3,699,000 for the same period in fiscal year 2007, a decrease of 11%. Operating expenses for the fourth quarter of fiscal year 2008 were $7,165,000 compared to $4,050,000. Net loss for the fourth quarter of fiscal year 2008 was $3,198,000 or $0.10 per diluted share, compared to a net loss for the fourth quarter of fiscal year 2007 of $107,000 or $0.00 per diluted share.

Corporate Update

Secretin (RG1068) for Imaging of the Pancreas

In March, we initiated a Phase 3 clinical trial to evaluate the use of RG1068, synthetic human secretin, to improve the assessment of pancreatic duct structures by magnetic resonance imaging (MRI). The Phase 3 study is a multi-center, baseline-controlled, single dose study in which approximately 250 patients will receive an unenhanced MRI followed by a secretin-enhanced MRI of the pancreas. The study is designed to assess the sensitivity and specificity of secretin-enhanced MRI to improve the ability to detect pancreatic duct abnormalities relative to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the assessment, diagnosis and treatment of diseases such as acute and chronic pancreatitis. The study is being conducted at approximately 30 clinical sites within the United States and Canada. In April, the U.S. Food and Drug Administration granted Fast Track Designation to our development program. Fast Track is a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need.

Uridine (RG2417) for Bipolar Disorder

Today, we announced that based on
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
3. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
4. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
8. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
11. Advance Nanotech Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... 2015  Caris Life Sciences® today announced the ... Intelligence®, the company,s panomic, comprehensive tumor profiling service, ... rare and difficult to treat gynecological cancers may ... to improve patient outcomes. These studies were presented ... of Gynecologic Oncology (SGO) 2015 Annual Meeting on ...
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... presentation of important study data showing the ... in 1,599 gynecologic cancer samples. Using Caris ... profiling service, researchers identified expression of programmed ... cancers independent of histology while its ligand ...
(Date:3/27/2015)... 2015 Earlier this year, the Capillus272Pro™ ... hair regrowth in adult men and women with androgenic ... Hamilton classifications of IIa-V and Fitzpatrick Classification of Skin ... products that over-promise and under-deliver, FDA Clearance underscores the ... confidence among more than 80 million men and women ...
(Date:3/27/2015)... März 2015  Peter Walter wurde als ... für seine bahnbrechende Arbeit ausgewählt, die sich ... werden, sowie für die Entschlüsselung der Komponenten ... Stress nutzen, der mit der Ansammlung von ... für Biochemie an der University of California, ...
Breaking Biology Technology:Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... Innocoll, Inc., a,privately held specialty pharmaceutical company, ... investment to raise $30 million through the ... placement with three,institutional investors led by Camulos ... and Morgan Stanley & Co, Incorporated. The ...
... is a new drug being,studied to prevent fractures in ... 3 clinical trial using denosumab were presented,Friday evening at ... from the Seattle Cancer Care Alliance., Denosumab is ... -- specialized cells that break down bone. Because it ...
... Per Acre Yield Advantage in Key ... Maturity Zone, ... showed that farmers who used DEKALB(R) corn seed stacked,with YieldGard VT Triple(TM) ... seed corn brands and,technologies in 2007., Data from nearly 1,700 on-farm ...
Cached Biology Technology:Innocoll Announces Closing of $30 Million Equity Financing Investment 2Innocoll Announces Closing of $30 Million Equity Financing Investment 3Innocoll Announces Closing of $30 Million Equity Financing Investment 4Innocoll Announces Closing of $30 Million Equity Financing Investment 5New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment 2Farmers Across the U.S. Realize Double-Digit Yield Advantage From DEKALB(R) Corn Seeds With Triple-Stacked Traits 2
(Date:3/31/2015)... , March 31, 2015   Guidepoint , ... launch of the Post-Surgical Pain Management TRACKER, part of ... tracking usage trends in the medical device and therapeutics ... to data including treatment volumes, market share, and adoption ... pain associated with joint surgery. The Post-Surgical ...
(Date:3/24/2015)... Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of ... report to their offering. This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... New Rochelle, NY, October 3, 2008Novel platform technologies and ... of molecular diagnostics, reports Genetic Engineering and Biotechnology ... products can be significant as Kalorama Information predicts that ... reach $5.4 billion in four years, according to an ...
... Case Western Reserve University School of Medicine has been ... Children,s Study, the National Institutes of Health,s comprehensive study on ... At a briefing today, NIH officials named ... 36 new and existing study centers which would recruit study ...
... R.I. [Brown University] Brown University, with lead partner ... awarded a $12-million, five-year contract to expand its participation ... aimed at improving child health. The National Institute ... the 27 Institutes and Centers at the National Institutes ...
Cached Biology News:Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics 2NIH selects Case Western Reserve University to participate in National Children's Study 2Brown University and Women & Infants Hospital expand national children's study to Bristol County 2Brown University and Women & Infants Hospital expand national children's study to Bristol County 3Brown University and Women & Infants Hospital expand national children's study to Bristol County 4
Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: